focus -WSS

focus

author：entertainment 2025-09-28 18:40:03 - browse：6487

Business standing in the middle of a maze near a bag with a dollar sign on it. -- biotech coverage from STAT — Adobe

Over the last year or two, something curious has started occurring in the conference rooms and private Zoom meetings of biotech venture capitalists.

Representatives from pension funds, college endowments, family offices, and other organizations with money to invest have become bolder in their requests, according to interviews with a host of VCs. They’re pushing not only for advantageous terms in a VC firm’s latest fund, but in some cases, have angled for equity in the firm itself. These types of conditions aren’t unheard of, but have become more frequent as venture capitalists have a harder time raising funds, and as outside investors feel empowered to ask for more bang for their buck.

“A lot is changing in venture fundraising right now,” said Nan Li, co-founder and managing partner of Dimension, which launched last January. Outside investors tried to ask for a piece of Dimension, but the new firm had more than enough interest in its first fund and was able to turn down those proposals. Two other young VC firms told STAT they’ve fielded similar requests, and one investment group reported that it had managed to negotiate an equity stake in a VC firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Clinical trials must include more disabled people

focus

WSS

Beware the threat of staffing cuts at the CDC

Dementia risk linked to living in disadvantaged areas: Study

Telehealth startups are trying to fill the menopause care vacuum

Thousands of UK hospital doctors walk out in the latest pay dispute, crippling health services

How a Boston hospital is priming medical residents to use GPT

Majority of Americans think Trump's Ga. election interference case is serious: POLL

focus

focus

leisure time

Medical records are filled with copy

The boys, now 6, who are gene therapy’s ‘edge case’ problem

Jerome Adams on the need for new antivirals for Covid

Trump cancels press conference intended to dispute Georgia election interference charges

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Judge denies Trump's request for new trial in E. Jean Carroll case

Duchenne breakthrough therapy leaves behind pioneering families

After a decade, new Gardasil ad campaign gets it (mostly) right

Psychedelics group wrestles with new pharma identity

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

hotspot

Patient advocates sound warning on FDA proposal on salt intake

Delta passengers in Vegas fall sick while waiting on flight in triple

ProMED sees offers of support, but its future remains unclear

When a patient nears the end, a feared therapy can comfort

Clinical trials must include more disabled people

Are infertility treatments 'essential' during the Covid

explore

focus

focus

entertainment